Peptide therapy cost without insurance, by peptide
Peptide therapy costs $93 to $330 a month without insurance at US telehealth programs, by peptide and program. Last checked November 20, 2026.
Lowest cash price on the chart: CoreAge Rx NAD+, from $93 a month. Read November 21, 2026.
These are cash prices for the named product and plan. A low first-month offer can renew at a higher price. For example, Embody lists sermorelin at $49 for the first month, then $99 a month. Check the form, the renewal bill, any membership fee and the cancellation terms before you choose. Read November 21, 2026.
Lowest cash prices on the chart
CoreAge Rxfrom $93 a month, no membership fee. No long-term contractNAD+ injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
CoreAge Rxfrom $93 a month, no membership fee. No long-term contractNAD+ nasal sprayChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
BiltRxfrom $97 a month, with consultation and shipping billed separatelyNAD+ injectionChecked November 21, 2026 on BiltRx's own pageSee prices
Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money
Peptide therapy cost by peptide
| Peptide | Lowest a month | Median | Highest a month |
|---|---|---|---|
| NAD+ cost | $93 | $165 | $235 |
| Sermorelin cost | $99 | $159 | $330 |
| Glutathione cost | $99 | $125 | $187 |
| BPC-157 cost | $119 | $159 | $199 |
| MOTS-c cost | $119 | $159 | $199 |
| Epitalon cost | $119 | $159 | $199 |
| TB-500 cost | $199 | $199 | $199 |
| Semax cost | $199 | $199 | $199 |
| KPV cost | $199 | $199 | $199 |
Sermorelin
NAD+
Glutathione
BPC-157
TB-500
MOTS-c
Epitalon
Semax
KPV
Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money
Programs pay us when you sign up through our links. Affiliate disclosure
Questions
What is the lowest peptide cash price on this chart?
CoreAge Rx NAD+, from $93 a month. Read November 21, 2026 from CoreAge Rx's own page.
How much does peptide therapy cost without insurance?
$93 to $330 a month at the US telehealth programs on this chart, by peptide and program: NAD+ $93 to $235; Sermorelin $99 to $330; Glutathione $99 to $187; BPC-157 $119 to $199; MOTS-c $119 to $199; Epitalon $119 to $199; TB-500 $199 to $199; Semax $199 to $199; KPV $199 to $199. These are cash prices, checked November 20, 2026.
When were these prices checked?
Each line carries the date its price was read. The oldest on this page is November 20, 2026.
Also priced on their own pages: PT-141 cost, NAD+ injection cost and glutathione injection cost.
Where to buy peptides legally and are peptides legal: the FDA status of each peptide.
Not medical advice.
FDA status
FDA status of the 9 products on this page
Sermorelin: The brand Geref was approved and discontinued, not withdrawn for safety.
NAD+: NAD is on the FDA's Category 1 list, substances pharmacies may compound while the agency reviews them.
Glutathione: Glutathione is on the FDA's Category 1 list, substances pharmacies may compound while the agency reviews them.
BPC-157: The FDA lists BPC-157 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.
TB-500: The FDA lists it among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.
MOTS-c: The FDA lists MOTs-C among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.
Epitalon: The FDA lists epitalon among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.
Semax: The FDA lists semax (heptapeptide) among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.
KPV: The FDA lists KPV among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn.